Welcome to our dedicated page for Swk Hldgs news (Ticker: SWKH), a resource for investors and traders seeking the latest updates and insights on Swk Hldgs stock.
SWK Holdings Corp (NASDAQ: SWKH) - a leader in specialized healthcare finance - provides investors and industry stakeholders with critical updates through this centralized news hub. Track all official announcements, strategic developments, and financial disclosures from the company pioneering non-dilutive funding solutions for life science innovators.
This resource delivers verified SWKH news including earnings reports, royalty financing agreements, partnership announcements, and regulatory filings. Investors gain timely access to:
- Quarterly financial performance updates
- Strategic acquisitions and asset purchases
- Enteris BioPharma development milestones
- Portfolio company progress reports
Bookmark this page for direct access to SWK Holdings' latest press releases and market-moving developments. Our curated news collection eliminates fragmented research, providing a reliable single source for monitoring the company's healthcare finance activities and pharmaceutical sector impact.
SWK Holdings Corporation (Nasdaq: SWKH) announced that its subsidiary, Enteris BioPharma, has received a $5 million milestone payment from Cara Therapeutics (Nasdaq: CARA) related to their licensing agreement for the Peptelligence® oral formulation technology utilized in Oral KORSUVA™. Enteris retains $3 million of this payment. This payment brings the total to $28 million since the license's inception. Enteris is also eligible for further milestone payments tied to Oral KORSUVA's development, with Cara planning to initiate a Phase 3 program in 2022.
SWK Holdings Corporation (Nasdaq: SWKH) announced receipt of a non-binding acquisition proposal from Carlson Capital, L.P. on November 23, 2021, offering $19.00 per share for all outstanding shares not held by Carlson. The Company's Board has established a special committee of independent directors to evaluate this proposal. The outcome remains uncertain, with no assurance of a definitive agreement or transaction completion. Meanwhile, the company emphasizes its focus on providing financing solutions in the healthcare sector through partnerships and its ownership of Enteris Biopharma.
Enteris BioPharma, a subsidiary of SWK Holdings (SWKH), published an article titled "The 505(b)(2) Pathway – Pharma's 'Goldilocks' Opportunity" in Pharma Tech Outlook. Authored by Gary Shangold, M.D., the article discusses the benefits of the 505(b)(2) regulatory pathway, which allows for innovative drug improvements without redundant studies, thus fostering innovation. It emphasizes the potential for commercial value and market expansion through effective application of this pathway in drug development.
SWK Holdings Corporation (SWKH) announced its third-quarter 2021 financial results, demonstrating a 12.7% increase in tangible book value per share, now $17.50. The finance receivables segment reported a 17.6% rise in adjusted non-GAAP net income, totaling $7.7 million, while total revenue decreased to $9.6 million from $10.6 million in Q3 2020. The finance portfolio yielded 18.8%, up from 17.4% year-over-year. The company's strategic review concluded, allowing a focus on specialty finance, with plans to increase leverage prudently to capitalize on market opportunities.
SWK Holdings Corporation (Nasdaq: SWKH) has completed a strategic review to maximize stockholder value, concluding no supported transaction was identified. The Board has approved a new streamlined business plan to enhance growth and capital allocation. CEO Winston Black highlighted a past deployment of over $600 million into 42 investments with a realized IRR of 20%. The company aims to leverage its assets and consider dividends or share repurchases to enhance shareholder returns. SWK believes its specialty finance and royalty portfolio hold substantial value beyond their GAAP carrying amounts.
Enteris BioPharma, a subsidiary of SWK Holdings (Nasdaq: SWKH), will participate in the virtual Partnership Opportunities in Drug Delivery (PODD) 2021 Conference on October 28-29, 2021. The company aims to engage with pharmaceutical executives about its innovative formulation technologies, Peptelligence® and ProPerma®, which facilitate oral delivery of challenging compounds. Enteris is advancing several programs leveraging these technologies, some already in late-stage clinical development. The conference emphasizes the growing interest in oral biologics delivery.
Enteris BioPharma, a subsidiary of SWK Holdings (Nasdaq: SWKH), will participate in the AAPS 2021 PHARMSCI 360 Conference from October 17-20, 2021 at the Pennsylvania Convention Center, Philadelphia. The conference offers in-person and virtual meeting options. Enteris will showcase its innovative drug delivery technologies, Peptelligence® and ProPerma®, during meetings with pharmaceutical executives. These technologies support oral delivery of complex drug compounds and are part of the company's CDMO services, which have gained significant interest from the pharmaceutical sector.
Enteris BioPharma, a subsidiary of SWK Holdings (SWKH), has completed a successful Phase 1 clinical trial for its optimized Peptelligence oral tablet formulation of leuprolide. The trial, involving 22 patients, demonstrated that the oral formulation can safely deliver higher doses, achieving blood concentrations comparable to traditional injection methods. Enteris' proprietary Peptelligence platform enables the oral delivery of peptides and small molecules, enhancing patient compliance. The company plans to advance this product for diseases responsive to GnRH agonists.
Enteris BioPharma, a subsidiary of SWK Holdings (Nasdaq: SWKH), has received the 2021 Best of Boonton Award in the Pharmaceutical Company category, marking its third consecutive win. The award recognizes Enteris' growth from a startup to an industry leader in oral delivery of therapeutics since 2013. CEO Rajiv Khosla highlighted the company's resilience during the COVID-19 pandemic, citing a facility expansion and key milestones in partnerships. Enteris is committed to addressing unmet clinical needs using its proprietary technologies, Peptelligence® and ProPerma™.
SWK Holdings Corporation (SWKH) reported strong financial results for Q2 2021, with total revenue reaching $22.3 million, a significant increase from $7.9 million in Q2 2020. The growth is attributed to a $10.3 million rise in the Pharmaceutical Development segment and a $4.1 million increase in Finance Receivables. Adjusted net income rose to $17.2 million, up from $4.0 million a year prior. The company also announced a $5.0 million share repurchase program and formed a Strategic Review Committee to explore options for maximizing shareholder value.